Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Phase 2MosliciguatNeutral

AI Analysis

Summary

Roivant will present topline results from the Phase 2 PHocus study of Mosliciguat in patients with PH-ILD at the ERS Congress 2026 on September 8, 2026, followed by an investor call.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Topline results presentation

Importance:6/10

Sentiment:

0.00

Phase 2Pulmonary HypertensionInterstitial Lung DiseaseData PresentationERS Congress

Related Companies

$ROIV

Read the original article

Published by yahoo_finance on September 6, 2026 5:00 AM

Read Original